The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2026 | WCLC 2026 highlights: T-DXd in HER2-mutant NSCLC and advances in targeted therapies
Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center, New York, NY, shares highlights from 2026 World Conference on Lung Cancer congress. Dr Drilon explores the increase in targeted therapies in the non-small cell lung cancer (NSCLC) space, including promising data from the DESTINY-Lung04 (NCT05048797) trial investigating first-line trastuzumab deruxtecan in patients with metastatic HER2-mutant NSCLC. This interview took place at the IASLC 2026 World Conference on Lung Cancer congress in Seoul, Republic of Korea.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
